We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
586. Anti-HIV-1 Neutralizing Antibody Gene Delivery to Rhesus Macaques and Rodents: A Novel Vaccination Approach.
- Authors
Clark, K. Reed; Jianchao Zhang; Montefiori, David C.; Johnson, Philip R.
- Abstract
We are continuing to develop a novel vaccination approach that is predicated on providing protective anti-HIV-1 humoral immune responses through antibody gene transfer. Our strategy is to utilize rAAV mediated antibody gene transfer to skeletal muscle to supply the host with a renewable source of anti-HIV-1 antibodies in their systemic circulation. The genes encode several rare, but broadly neutralizing scFv HIV-1 antibodies (X5, 3B3, and 3B3-hCC). One potential challenge to this approach is whether therapeutic levels of NAbs are achievable. Data from previous passive immunization protection studies in primates indicate that protective levels may be achieved with serum concentrations of potent NAbs in the range of 50 -100 ug/ml. To address this issue, we have optimized several variables for efficient antibody gene delivery and expression; these include rAAV serotype, antibody genetic fusions for increased half- life, and inclusion of cis sequences for maximal expression. This has resulted in increased antibody levels by greater than 100-fold over our initial efforts. Significantly, optimization of delivery and expression parameters has yielded NAb levels exceeding 500 ug/ml in mice and up to 43 ug/ml in primates - levels which approach or exceed the predicted therapeutic range. Consistent with their broad neutralization activity, animal sera containing X5 and 3B3-hCC from rAAV vaccinated mice and primates possess potent in vitro neutralization activity against TCLA and primary HIV-1 single- cycle HIV-1 pseudoviruses as measured by reduction of luciferase reporter gene activity in TZM-BL cells. These data now set the stage for future challenge experiments to determine whether the in vivo levels observed to date provide protection (reduction in viral load) upon a virulent SHIV challenge.Molecular Therapy (2006) 13, S226–S226; doi: 10.1016/j.ymthe.2006.08.660
- Subjects
AIDS prevention; GENETIC transformation; RHESUS monkeys; LABORATORY rodents; VACCINATION; IMMUNE response
- Publication
Molecular Therapy, 2006, Vol 13, pS226
- ISSN
1525-0016
- Publication type
Article
- DOI
10.1016/j.ymthe.2006.08.660